# Takeda Pharmaceutical Co Ltd: Form 20-F for the period ended Mar 31, 2020

- Company: [Takeda Pharmaceutical Co Ltd](/companies/tak.md) (CIK 1395064)
- Form: 20-F
- Filed: 2020-06-24
- Accepted by EDGAR: Jun 24, 2020, 06:21 ET
- Period: 2020-03-31
- Accession: 0001395064-20-000110
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/takeda_20200331x20-f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2019-04-01 to 2020-03-31 | JPY 3.29tn | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2019-04-01 to 2020-03-31 | JPY 1.09tn | ifrs-full:CostOfSales |
| Operating income | 12 months, 2019-04-01 to 2020-03-31 | JPY 100.41bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2019-04-01 to 2020-03-31 | −JPY 105.04bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2019-04-01 to 2020-03-31 | JPY 44.24bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2019-04-01 to 2020-03-31 | JPY 28.25 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2019-04-01 to 2020-03-31 | JPY 28.41 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2019-04-01 to 2020-03-31 | JPY 669.75bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2019-04-01 to 2020-03-31 | JPY 127.08bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2020-03-31 | JPY 637.61bn | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2020-03-31 | JPY 2.47tn | ifrs-full:CurrentAssets |
| Total assets | at 2020-03-31 | JPY 12.82tn | ifrs-full:Assets |
| Current liabilities | at 2020-03-31 | JPY 2.18tn | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2020-03-31 | JPY 8.09tn | ifrs-full:Liabilities |
| Shareholders' equity | at 2020-03-31 | JPY 4.72tn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2020-03-31 | 1,557,765,596 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/takeda_20200331x20-f.htm

Filed Jun 24, 2020.
Source: SEC EDGAR, the filing index for accession 0001395064-20-000110. Last ingested by Listed: Nov 5, 2026, 16:17 ET. No prices; not investment advice.